WEAV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
WEAV is not a good buy right now for an impatient buyer. The chart is still in a confirmed downtrend (bearish moving-average stack and weakening MACD), and there are no Intellectia buy signals today to override that. While the stock is near support (~6.36) and fundamentals are improving, the near-term setup favors waiting for a clear reclaim above ~6.70 (pivot) or momentum reversal rather than buying immediately into weakness.
Trend/momentum: Bearish. The moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend. MACD histogram is negative (-0.0634) and expanding lower, suggesting downside momentum is still building. RSI(6) at ~34 is depressed but not signaling a confirmed reversal. Key levels: Price ~6.43 is sitting just above S1 support at 6.358; a break risks a move toward S2 at 6.143. Upside resistance is the pivot at 6.705, then R1 7.053. Pattern/near-term odds: Similar-pattern model shows higher probability of a small next-day dip (-1.37%) but a positive next-week move (+5.06%), which fits a potential bounce attempt—however, the trend remains bearish until reclaiming resistance.
Intellectia Proprietary Trading Signals
Fundamental improvement: 2025/Q3 revenue grew 17.1% YoY and losses narrowed materially (net income improved 47.4% YoY; EPS improved 37.5% YoY), supporting a potential rerating if growth durability persists.
Valuation/expectations setup: Analysts’ targets remain above the current price (e.g., $10 and $8 vs ~$6.4), suggesting upside if execution improves.
Options sentiment: Strong call skew may support short-term bounce attempts if the stock holds support.
Technical downtrend: Bearish MA stack and deteriorating MACD increase the probability that support breaks before a sustained reversal forms.
Analyst tone/catalyst timing: Raymond James downgraded from Strong Buy to Outperform and reduced PT ($12 to $10), citing tougher SMB software environment and delayed visibility into organic re-acceleration and profitability path.
No fresh news catalysts: No recent news flow to trigger immediate rerating or momentum shift.
Influential/political activity: No recent congress trading data and no notable politician activity provided.
Latest quarter (2025/Q3): Revenue $61.34M (+17.10% YoY), showing solid growth. Profitability is improving but still negative: net income -$8.67M (loss narrowed ~47.44% YoY) and EPS -$0.11 (improved 37.50% YoY). Gross margin remained strong at ~72.29% (slightly up YoY), indicating healthy unit economics and potential operating leverage if growth stabilizes and opex scales.
Recent changes: Ratings/targets have trended down. Raymond James (2026-01-06) downgraded to Outperform from Strong Buy and cut PT to $10 from $12; Citi (2025-11-03) kept Neutral and lowered PT to $8 from $9. Wall Street pros: Sees durability in growth profile and meaningful upside versus current price if organic re-acceleration becomes visible and profitability trajectory becomes more consistent. Wall Street cons: Near-term environment for SMB software is tougher, catalysts may take longer, and the market may not rerate the stock until clearer acceleration/profit progress is evident.
